ストックスクリーナーアプリを入手
0.2276
2.61%
-0.0061
前日終値:
$0.2337
開ける：
$0.2329
24時間の取引高:
8.45M
Relative Volume:
0.45
時価総額：
$6.93M
収益：
$94,000
当期純損益:
$-13.28M
株価収益率:
-0.0312
EPS:
-7.2965
ネットキャッシュフロー:
$-11.67M
1週間 パフォーマンス:
-11.92%
1か月 パフォーマンス:
-13.46%
6か月 パフォーマンス:
-67.05%
1年 パフォーマンス:
-90.66%
1日の値動き範囲:
$0.2266
$0.24
1週間の範囲:
$0.2015
$0.3713
52週間の値動き範囲:
$0.1901
$2.977
AIM ImmunoTech Inc Stock (AIM) Company Profile
Compare AIM vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.2276 | 7.70M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech highlights pancreatic cancer program momentum - scanx.trade
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
AIM (AIM) Earnings Snapshot: EPS Does Not Reach the Reported Estimate in the Latest Reading; After Earnings: The Share Price Adds 1.84% in the Latest SessionHigh Estimate Range - vinanet.vn
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM Q2 2026 Earnings: Wider-than-Expected Loss Prompts Investor CautionFinal Results - vinanet.vn
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$AIM ImmunoTech (AIM.US)$ - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times
AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan
Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia
AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative
AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer - The Manila Times
AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan
AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com Nigeria
AIM ImmunoTech signs $1.5 million manufacturing agreement with Sterling Pharma - Investing.com
AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen - Stock Titan
AIM ImmunoTech (AIM) Climbs 7.98% as Biotech Micro-Cap Tests Key Resistance at $0.29PCR Spike - dars.gov.et
AIM ImmunoTechDuripanc Overall Survival En - Moomoo
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point - Yahoo Finance
AIM ImmunoTech Q1 2026 Earnings: Loss Widens 52.5% Past Estimates; Shares Rally 8.09%Analyst Coverage Count - dars.gov.et
AIM Q1 2026 Earnings: EPS Misses by 52.53% Yet Shares Rally 8.09%Earnings Recovery Stocks - vinanet.vn
AIM Q1 2026 Earnings: Wider-than-Expected Loss Misses Estimates; Shares Rise 8.09%EBITDA Analysis - Vinanet
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Cash Flow - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.254|Chg%:+0.005 - TradingKey
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Balance Sheet - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.241|Chg%:-0.009 - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aim Immunotech Inc. (AIM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Aim Immunotech Inc. (AIM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
AIM ImmunoTech Inc. Revenue Breakdown – AMEX:AIM - TradingView
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM ImmunoTech Inc. (AIM) stock price, news, quote and history - Yahoo Finance Australia
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates as Company Continues Clinical DevelopmentForward Guidance Trends - vinanet.vn
AIM ImmunoTech Inc (AIM) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):